Healthcare -
Biotechnology - NASDAQ - US
$ 0.36
2.86 %
$ 58.8 M
Market Cap
None
P/E
1. INTRINSIC VALUE
Balance Sheet
Quantum-Si incorporated
| Current Assets | 218 M |
| Cash & Short-Term Investments | 210 M |
| Receivables | 1.33 M |
| Other Current Assets | 7.07 M |
| Non-Current Assets | 29.9 M |
| Long-Term Investments | 0 |
| PP&E | 29.1 M |
| Other Non-Current Assets | 808 K |
| Current Liabilities | 18.2 M |
| Accounts Payable | 1.93 M |
| Short-Term Debt | 3.7 M |
| Other Current Liabilities | 12.6 M |
| Non-Current Liabilities | 14.3 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 14.3 M |
EFFICIENCY
Earnings Waterfall
Quantum-Si incorporated
| Revenue | 3.06 M |
| Cost Of Revenue | 1.46 M |
| Gross Profit | 1.6 M |
| Operating Expenses | 110 M |
| Operating Income | -109 M |
| Other Expenses | -7.57 M |
| Net Income | -101 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Quantum-Si incorporated
| Net Income | -101 M |
| Depreciation & Amortization | 4.6 M |
| Capital Expenditures | -4.58 M |
| Stock-Based Compensation | 8.89 M |
| Change in Working Capital | 0 |
| Others | -275 K |
| Free Cash Flow | -92.4 M |
Wall Street Analysts Price Targets
Quantum-Si incorporated
QSIAW has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
QSIAW does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Quantum-Si incorporated
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
8. Profile
Summary
Quantum-Si incorporated QSIAW
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 58.8 M
Dividend Yield
0.00%
Description
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.
Contact
29 Business Park Drive, Branford, DE, 06405
https://www.quantum-si.com
IPO
Date
None
Employees
149
Officers
Mr. Jeffrey Alan Hawkins
President, Chief Executive Officer & Director
Dr. Christian Lapointe J.D., Ph.D.
General Counsel & Corporate Secretary
Mr. Todd C. Bennett
Chief Commercial Officer
Ms. Lindsay Thompson
Chief Human Resources Officer
Ms. Katherine Atkinson
Senior Vice President of Demand Generation & Corporate Brand
Mr. Todd Rearick
Chief Technology Officer
Dr. Jonathan M. Rothberg Ph.D.
Founder & Executive Director
Dr. John S. Vieceli Ph.D.
Chief Product Officer